QuantiFERON Change During Anti-tuberculosis Medication

This study has been completed.
Sponsor:
Information provided by:
Armed Forces Capital Hospital, Republic of Korea
ClinicalTrials.gov Identifier:
NCT01038830
First received: December 23, 2009
Last updated: June 11, 2010
Last verified: December 2009
  Purpose

The aim of this study is to evaluate the change of QuantiFERON-TB gold in tube assay (QFT) during the treatment of active tuberculosis.


Condition
Tuberculosis
Interferon-gamma Release Assay

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Change in Level of Interferon-gamma Assay in Active Tuberculosis Patients During Treatment

Resource links provided by NLM:


Further study details as provided by Armed Forces Capital Hospital, Republic of Korea:

Estimated Enrollment: 50
Study Start Date: May 2008
Study Completion Date: May 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Detailed Description:

Patients with active pulmonary tuberculosis are enrolled and, QFTs are performed for each subjects before treatment and 1, 3, 6 months after treatment. Investigators check the level of interferon-gamma, and reversion and conversion of this test.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Young healthy subjects in Korean military

Criteria

Inclusion Criteria:

  • All subjects with active tuberculosis

Exclusion Criteria:

  • Subjects who cannot complete study
  • Subjects who have taken anti-tuberculosis medication for more than a month before visit of our hospital
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01038830

Locations
Korea, Republic of
Armed Forces Capital Hospital
Seongnam, Gyeonggi-do, Korea, Republic of, 463-040
Sponsors and Collaborators
Armed Forces Capital Hospital, Republic of Korea
  More Information

No publications provided

Responsible Party: Sei Won Lee/Division chief of pulmonology, Armed Forces Capital Hospital
ClinicalTrials.gov Identifier: NCT01038830     History of Changes
Other Study ID Numbers: QFTchange
Study First Received: December 23, 2009
Last Updated: June 11, 2010
Health Authority: Korea: Food and Drug Administration

Additional relevant MeSH terms:
Tuberculosis
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Mycobacterium Infections

ClinicalTrials.gov processed this record on October 20, 2014